Suppr超能文献

C-原癌基因在人良性和恶性肾组织中的表达

C-met proto-oncogene expression in benign and malignant human renal tissues.

作者信息

Pisters L L, el-Naggar A K, Luo W, Malpica A, Lin S H

机构信息

Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

出版信息

J Urol. 1997 Sep;158(3 Pt 1):724-8. doi: 10.1097/00005392-199709000-00009.

Abstract

PURPOSE

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen to renal epithelial cells in vitro and in vivo. HGF/SF signals through its receptor which is coded by the c-met proto-oncogene. We hypothesized that altered expression of the HGF/SF receptor, c-met, may be involved in the pathogenesis of certain renal cell carcinomas. Our objectives were to 1) assess the presence and localization of c-met protein in benign and malignant human renal tissues, and 2) correlate the presence of c-met protein with renal carcinoma histological subtype, tumor stage and tumor grade.

MATERIALS AND METHODS

Immunohistochemical analysis of c-met protein was performed in 41 normal and malignant human renal samples.

RESULTS

c-met Immunostaining was detected in the normal kidney tissue in all 41 samples. In the normal kidney c-met immunostaining was limited to the cell membrane and/or cytoplasm of epithelial cells in specific tubular segments, including the proximal convoluted tubule, thin and thick limbs of the loop of Henle, and the collecting duct. The glomeruli, distal convoluted tubule and stroma were consistently negative for c-met staining. c-met Immunostaining was detected in 68% of renal cell carcinomas and was more common in higher nuclear grade cancers (p < 0.034).

CONCLUSIONS

The c-met receptor is present in specific tubular segments in the normal kidney and is frequently expressed in higher nuclear grade renal cancers, suggesting a role in renal carcinoma progression. Future studies should evaluate the biological significance of the HGF/ SF-c-met pathway in normal renal physiology, and renal cancer growth and progression.

摘要

目的

肝细胞生长因子/离散因子(HGF/SF)在体外和体内都是肾上皮细胞的一种强效促有丝分裂原。HGF/SF通过其由c-met原癌基因编码的受体发出信号。我们推测,HGF/SF受体c-met表达的改变可能参与某些肾细胞癌的发病机制。我们的目标是:1)评估c-met蛋白在良性和恶性人类肾组织中的存在及定位,以及2)将c-met蛋白的存在与肾癌的组织学亚型、肿瘤分期和肿瘤分级相关联。

材料与方法

对41例正常和恶性人类肾样本进行c-met蛋白的免疫组织化学分析。

结果

在所有41个样本的正常肾组织中均检测到c-met免疫染色。在正常肾脏中,c-met免疫染色仅限于特定肾小管节段上皮细胞的细胞膜和/或细胞质,包括近端曲管、髓袢细段和粗段以及集合管。肾小球、远端曲管和间质的c-met染色始终为阴性。在68%的肾细胞癌中检测到c-met免疫染色,在高核分级癌症中更常见(p < 0.034)。

结论

c-met受体存在于正常肾脏的特定肾小管节段中,且在高核分级肾癌中频繁表达,提示其在肾癌进展中起作用。未来的研究应评估HGF/SF-c-met途径在正常肾脏生理学以及肾癌生长和进展中的生物学意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验